Protagonist Therapeutics, Inc.
PTGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,376,486 | $1,301,588 | $535,051 | $1,584,244 |
| - Cash | $97,249 | $186,727 | $125,744 | $123,665 |
| + Debt | $10,866 | $1,141 | $3,656 | $5,858 |
| Enterprise Value | $2,290,103 | $1,116,002 | $412,963 | $1,466,437 |
| Revenue | $434,433 | $60,000 | $26,581 | $27,357 |
| % Growth | 624.1% | 125.7% | -2.8% | – |
| Gross Profit | $434,433 | $60,000 | $26,581 | $27,357 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $253,669 | -$90,340 | -$128,004 | -$123,070 |
| % Margin | 58.4% | -150.6% | -481.6% | -449.9% |
| Net Income | $275,188 | -$78,955 | -$127,393 | -$125,551 |
| % Margin | 63.3% | -131.6% | -479.3% | -458.9% |
| EPS Diluted | 4.23 | -1.39 | -2.52 | -2.65 |
| % Growth | 404.3% | 44.8% | 4.9% | – |
| Operating Cash Flow | $184,152 | -$70,236 | -$108,137 | -$107,865 |
| Capital Expenditures | -$1,355 | -$609 | -$795 | -$1,101 |
| Free Cash Flow | $182,797 | -$70,845 | -$108,932 | -$108,966 |